Business Context and Reporting Period
This Form 8-K is filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) for the reporting date of March 19, 2019. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Waltham, MA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The Company received formal notice from the Nasdaq Listing Qualifications Staff on March 19, 2019, that its common stock will be subject to delisting from The Nasdaq Capital Market on March 28, 2019. This action is due to continued non-compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"), which requires a closing bid price of at least $1.00 per share. The Company failed to regain compliance by the end of its second 180-day grace period on March 18, 2019.
Outlook, Risks, and Management Commentary
- Management Action: The Company plans to timely request a hearing before the Nasdaq Hearings Panel. This request will stay the delisting action pending the Panel's decision.
- Strategy: At the hearing, the Company intends to present a plan to evidence compliance with the Bid Price Rule and request an extension of time. Previous filings indicated an intention to cure the deficiency via a reverse stock split if necessary.
- Risks: There are no assurances that the Panel will grant the request for continued listing or that the Company will achieve compliance within any granted extension.
- Trading Status: The common stock will continue to trade on The Nasdaq Capital Market under the symbol "EYEG" pending the conclusion of the hearing process.
Investor Verification Checklist
- Verify the current status of the Nasdaq Hearings Panel decision regarding the delisting notice.
- Confirm whether the Company has executed a reverse stock split or other capital structure changes to address the bid price deficiency.
- Monitor the closing bid price of the common stock to determine if it has sustained a level above $1.00.
- Check for subsequent filings regarding the outcome of the hearing or potential transfer to an alternative trading venue.